The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC), to treat relapsed or ...
GSK on Monday said its drug Blenrep outperformed Johnson & Johnson’s Darzalex in a clinical trial of people with the blood cancer multiple myeloma, potentially cracking open the door to Blenrep’s ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
Two of my recent post topics (on antibody-drug conjugates and on accelerated approval) have intersected today. Median progression-free survival was actually better with Blenrep, but the main way to ...
The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...
(RTTNews) - GSK plc (GSK, GSK.L) issued an update on FDA advisory committee review of Blenrep combinations for patients with relapsed/refractory multiple myeloma. GSK said it remains confident in the ...
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma in ...
Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found. The treatment of Blenrep (belantamabmafodotin) alone ...
GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...
During the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) meeting this July, the CHMP recommended the approval of two biologics and one biosimilar: GlaxoSmithKline’s Blenrep (belantamab ...
Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration (FDA) ...
LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback